BLCO vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 2/9, indicating weak operational and balance sheet performance. Despite a reasonable Price/Book of 0.94 and a Debt/Equity ratio of 0.76, the company is unprofitable with a negative ROE of -4.50% and a profit margin of -6.13%. Earnings have collapsed year-over-year (-147.1%) and the last four quarters missed estimates by an average of -154.31%, signaling deteriorating fundamentals. While revenue growth of 7.10% and a gross margin above 59% provide some operational strength, the persistent earnings deterioration and lack of profitability undermine valuation support.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BLCO vs JNJ: Head-to-Head Comparison
This page compares Bausch + Lomb Corporation (BLCO) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.